ArticleInternational journal of molecular sciences2026
Dissociated Humoral and Cellular Immune Responses to Recombinant Zoster Vaccine in Myeloproliferative Neoplasms Under JAK Inhibition: A Pilot Study.
Julio Torres-González, Blanca O'Donnell-Cortés, Rodolfo Matías Ortiz-Flores, Dariusz Piotr Narankiewicz Talarczyk, Borja Cidoncha-Morcillo, Fernando Fariñas-Guerrero, María Rodríguez-González, Regina García-Delgado, Alejandro Escamilla-Sánchez
Abstract read
In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Julio Torres-GonzálezBE21-Hematología e Inmunoterapia, IBIMA Plataforma BIONAND, Avenida Severo Ochoa 35, 29590 Málaga, Spain.
Blanca O'Donnell-CortésDepartamento de Salud Pública y Psiquiatría, Universidad de Málaga, 29010 Málaga, Spain.ORCID 0009-0005-5295-4062 Rodolfo Matías Ortiz-FloresBE21-Hematología e Inmunoterapia, IBIMA Plataforma BIONAND, Avenida Severo Ochoa 35, 29590 Málaga, Spain.ORCID 0000-0003-4509-0161 Dariusz Piotr Narankiewicz TalarczykÁrea A-23 Medicina Preventiva y Salud Pública, IBIMA Plataforma BIONAND, Instituto de Investigación Biomédica de Málaga, Avenida Severo Ochoa 35, 29590 Málaga, Spain.
Borja Cidoncha-MorcilloUGC Hematología y Hemoterapia, Hospital Universitario Virgen de la Victoria, Campus de Teatinos, s/n, 29010 Málaga, Spain.
Fernando Fariñas-GuerreroInstituto de Hematología, Inmunología y Biología Médica Avanzada (HEMOINMUN), 29590 Málaga, Spain.
María Rodríguez-GonzálezUGC Hematología y Hemoterapia, Hospital Universitario Virgen de la Victoria, Campus de Teatinos, s/n, 29010 Málaga, Spain.
Regina García-DelgadoBE21-Hematología e Inmunoterapia, IBIMA Plataforma BIONAND, Avenida Severo Ochoa 35, 29590 Málaga, Spain.
Alejandro Escamilla-SánchezBE21-Hematología e Inmunoterapia, IBIMA Plataforma BIONAND, Avenida Severo Ochoa 35, 29590 Málaga, Spain.ORCID 0000-0001-9135-5330 Funding
GlaxoSmithKline (United States)
6 · The paper itselfAbstract
Patients with myeloproliferative neoplasms (MPN) are at increased risk of herpes zoster, particularly during Janus kinase inhibitor (JAKi) therapy, yet the immunogenicity of recombinant zoster vaccine (RZV) in this setting remains incompletely characterized. We performed a prospective pilot translational study including 18 patients with MPN and a small age-matched healthy donor group (
Indexed as
Herpes ZosterHerpes Zoster VaccineImmunity, CellularImmunity, HumoralJanus Kinase InhibitorsMyeloproliferative DisordersAgedAntibodies, ViralCytokinesFemaleHerpesvirus 3, HumanHumansImmunoglobulin GMaleMiddle AgedPilot ProjectsAntibodies, ViralCytokinesHerpes Zoster VaccineImmunoglobulin GJanus Kinase InhibitorsVaccines, Syntheticcellular immunityherpes zosterhumoral immunityJAK inhibitorsmyeloproliferative neoplasmsrecombinant zoster vaccine
Identifiers
PMID42353257
PMCPMC13300440
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390